StocksMedium•4 November 2026•
1 min read
UroGen Pharma Q3 Revenue Jumps 35% as FDA Accepts UGN-103 Application
Key Facts
1UroGen Pharma reported $68.0 million in ZUSDURI revenue for Q3 2026, representing 35% quarter-over-quarter growth.
2The FDA accepted the NDA for UGN-103 for review, with a PDUFA goal date set for June 14, 2027.
UroGen Pharma reported $68.0 million in ZUSDURI revenue for the third quarter of 2026, marking a 35% increase compared to the previous quarter. GlobeNewswire reported that the FDA has accepted the New Drug Application for UGN-103 for review, setting a PDUFA goal date of June 14, 2027.
URGN closed at $34.4 on November 3, 2026, after reaching a session high of $34.97 and a low of $34. The financial performance and regulatory milestone follow the company's continued progress on its mitomycin-based formulations and the expansion of its clinical pipeline.